PMID: 8950314Jan 1, 1996Paper

Emerging paradigms in granulocyte-macrophage colony-stimulating factor signaling

Life Sciences
J Gomez-Cambronero, C Veatch

Abstract

The myelomonocytic lineage of hematopoiesis is regulated by the growth factor granulocyte-macrophage colony-stimulating factor (GM-CSF). This cytokine has proven to be safe for use in coordination with the treatments for bone marrow transplants and acute myelogenous leukemia. GM-CSF and related cytokines operate through specific receptors in the membranes of target cells of the myelopoietic lineages (both immature and mature cells). The exact signal transduction mechanisms in the cell are only beginning to be clarified and involve a plethora of signaling molecules. With a wealth of new information from studies in GM-CSF-induced cell activation, three major experimental approaches are emerging as gold standards in the exploration of those signaling pathways initiated by hematopoietic growth factors. We consider here: (1) a protein-protein interaction, as exemplified by the association between the cytokine membrane receptor and JAK kinase; (2) a covalent modification of an enzyme, as studied in the phosphorylation of MAP kinase; and (3) a protein-DNA interaction, as demonstrated by the translocation of STAT from the cytosol to the nucleus where it can bind to the promoters of specific genes.

References

Jan 1, 1990·Annual Review of Biochemistry·K I AraiT Yokota
Jan 1, 1995·Annual Review of Immunology·J N IhleO Silvennoinen
Apr 1, 1995·Journal of Leukocyte Biology·G M Johnson, J Gomez-Cambronero
Jun 1, 1995·Molecular and Cellular Biology·L M KarnitzR T Abraham
Sep 1, 1993·Protein Science : a Publication of the Protein Society·A WlodawerA Gustchina

❮ Previous
Next ❯

Citations

Apr 22, 2017·Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism·Hu ZhangDeshu Shang
Dec 21, 2000·American Journal of Physiology. Cell Physiology·J A LehmanJ Gómez-Cambronero
Aug 28, 1998·Cellular Signalling·J Gomez-Cambronero, P Keire
Sep 26, 2006·Biochemical and Biophysical Research Communications·Jin-Wen Huang, Nin-Nin Chuang

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Related Papers

Proceedings of the National Academy of Sciences of the United States of America
T K SenguptaL B Ivashkiv
Science's STKE : Signal Transduction Knowledge Environment
Curt M Horvath
© 2021 Meta ULC. All rights reserved